Pareek, M; Watson, JP; Ormerod, LP; Kon, OM; Woltmann, G; White, PJ; Abubakar, I; Lalvani, A; (2011) Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. The Lancet infectious diseases, 11 (6). pp. 435-44. ISSN 1473-3099
DOI: https://doi.org/10.1016/S1473-3099(11)70069-X

Downloaded from: http://researchonline.lshtm.ac.uk/504/

DOI: https://doi.org/10.1016/S1473-3099(11)70069-X

Usage Guidelines:

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis

Manish Pareek, John P Watson, L Peter Ormerod, Onn Min Kon, Gerrit Woltmann, Peter J White, Ibrahim Abubakar, Ajit Lalvani

Summary

Background Continuing rises in tuberculosis notifications in the UK are attributable to cases in foreign-born immigrants. National guidance for immigrant screening is hampered by a lack of data about the prevalence of, and risk factors for, latent tuberculosis infection in immigrants. We aimed to determine the prevalence of latent infection in immigrants to the UK to define which groups should be screened and to quantify cost-effectiveness.

Methods In our multicentre cohort study and cost-effectiveness analysis we analysed demographic and test results from three centres in the UK (from 2008 to 2010) that used interferon-γ release-assay (IGRA) to screen immigrants aged 35 years or younger for latent tuberculosis infection. We assessed factors associated with latent infection by use of logistic regression and calculated the yields and cost-effectiveness of screening at different levels of tuberculosis incidence in immigrants’ countries of origin with a decision analysis model.

Findings Results for IGRA-based screening were positive in 245 of 1229 immigrants (20%), negative in 982 (80%), and indeterminate in two (0·2%). Positive results were independently associated with increases in tuberculosis incidence in immigrants’ countries of origin (p=0·0006), male sex (p=0·046), and age (p<0·0001). National policy thus far would fail to detect 71% of individuals with latent infection. The two most cost-effective strategies were to screen individuals from countries with a tuberculosis incidence of more than 250 cases per 100 000 (incremental cost-effectiveness ratio [ICER] was £17 956 (£1=US$1·60) per prevented case of tuberculosis) and at more than 150 cases per 100 000 (including immigrants from the Indian subcontinent), which identified 92% of infected immigrants and prevented an additional 29 cases at an ICER of £20 819 per additional case averted.

Interpretation Screening for latent infection can be implemented cost-effectively at a level of incidence that identifies most immigrants with latent tuberculosis, thereby preventing substantial numbers of future cases of active tuberculosis.

Introduction

Although tuberculosis prevails in mainly high-burden developing countries, cases in immigrants in many low-incidence countries are increasing substantially.1 This changing pattern of disease is clear in the UK where, between 1998 and 2009, tuberculosis notifications have risen by 46%, from 6167 cases to 9040, with much of this rise fuelled by the 98% increase in cases from overseas.2,3 These individuals account for nearly three-quarters of all tuberculosis notifications in the UK with an incidence that is 20 times higher than in UK-born individuals (89 cases per 100 000 people per year vs 4 per 100 000).3 The evolving epidemiology in high-income countries is driven mainly by migration of individuals from countries with a high burden of disease, such as sub-Saharan Africa and the Indian subcontinent,4,5 and by the reactivation of latent tuberculosis infection that was acquired before migration.6 These factors result in a high incidence of tuberculosis in immigrants in the first 2–5 years after migration (with about 50% of foreign-born cases presenting in the first 5 years after migration), which then decreases over time.7,8

Changes in incidence have renewed interest in tuberculosis screening of immigrants.9 Data in several high-income countries suggest that screening for latent infection is highly variable—both in which immigrants are screened, and how they are screened.10 UK national policy specifies port-of-entry identification and screening with chest radiographs for immigrants from countries with a tuberculosis incidence of more than 40 cases per 100 000 population per year who intend to stay in the UK for more than 6 months. The aim of this initial screening is to detect active pulmonary tuberculosis,11 and results determine the subsequent actions taken by the individual’s local tuberculosis services.

Actions should be undertaken in line with national guidelines for tuberculosis control.12 For most immigrants with normal chest radiographs, since 2006, the National Institute for Health and Clinical Excellence (NICE) recommends that local tuberculosis services should screen specific subgroups of new entrants for latent infection, including children aged less than 16 years from countries with a tuberculosis incidence or more than 40 per 100 000 per year, and 16–35-year-olds from either sub-Saharan...
Panel 1: Model assumptions of the health economic model

- Immigrants are screened for latent tuberculosis infection at the start of the 20-year time line
- All IGRA results are determinate and no repeat testing is needed
- At the time of screening the immigrants there are no prevalent cases of active tuberculosis in the cohort
- There are no HIV-coinfected individuals in the cohort
- All active cases are caused by a tuberculosis strain that is fully drug sensitive
- In individuals with latent infection who are treated with chemoprophylaxis, a 3-month course of rifampicin and isoniazid has the same effectiveness as 6 months of isoniazid
- Individuals who start chemoprophylaxis and subsequently develop drug-induced liver injury that does not resolve are assumed to complete only 4 weeks of therapy, which affords no reduction in the risk of progressing to active infection
- An individual with latent tuberculosis who has completed successful chemoprophylaxis is assumed to have cleared the infection with Mycobacterium tuberculosis and will not experience any further outcomes in the time course of the model
- An individual who does not have latent infection on arrival in the UK does not become infected during the period of the model
- Data for the test performance of the IGRA were based on the most recent meta-analysis obtained from meta-analyses in which sensitivity was calculated with culture-confirmed active tuberculosis as the reference standard; specificity was calculated from BCG-vaccinated individuals at low risk of infection
- All individuals who are diagnosed with active tuberculosis are assumed to accept treatment for active infection and to complete the 6-month course of drugs

IGRA= interferon-γ release assays.

Figure 1: Study flow diagram

1633 invited to be screened

*269 did not attend

1364 attended

3 refused screening

1361 screened

132 excluded from analysis:
57 resident in UK>5 years
60 duration in UK unknown
5 cases of active tuberculosis diagnosed
2 with past history of tuberculosis
5 country of origin not recorded
1 IGRA result not recorded
1 demographic data missing
1 UK born

1229 included in final analysis

countries or from those with a disease incidence of more than 500 per 100 000 per year. Individuals older than 35 years are not screened because the risks of chemoprophylaxis outweigh the potential benefits.12

The rationale supporting this screening approach remains unclear, especially because data are scarce for the prevalence of latent infection in new immigrants as measured by interferon-γ release assays (IGRAs).13 Furthermore, although NICE’s recommendation for the two-step method of screening (ie, tuberculin skin-test plus confirmatory IGRA) has been adopted in most European countries, the USA, and many centres in the UK increasingly use one-step IGRA testing to screen for latent infection,14,15 probably because of this test’s high specificity.16–18 Additional reasons for the use of the one-step test include evidence that IGRAs might be able to predict the development of active tuberculosis from latent infection,19–28 and uncertainty about the optimum cutoff for a positive skin test in the context of previous BCG vaccination.29 We did this multicentre cohort study to compute yields from, and cost-effectiveness of, screening for latent infection at different thresholds in relation to incidence of tuberculosis in immigrants’ countries of origin.

Methods

Study design and participants

We did this prospective multicentre study and cost-effectiveness analysis of immigrant screening in three centres in the UK: Westminster, London; Leeds, Yorkshire; and Blackburn, Lancashire. Together these centres serve 1.6 million people of whom 6.5% (IQR 4.3%–9.9%) are foreign born.31 Between 2007 and 2009, the average 3-year notifications in these centres ranged from 54 to 126, and incidence varied from 16 to 33 cases per 100 000 population per year.32

Participants were foreign-born new entrants (arrival within the past 5 years) who were aged 35 years or younger and who were referred for and underwent tuberculosis screening between Jan 1, 2008, and July 31, 2010. Referrals to these centres were made either through port-of-entry screening systems, health-protection units, or after registration with primary-care services. Ethical approval was not needed because the study used fully anonymised observational data that were obtained as part of an assessment of routine clinical service.

Screening and management

We first screened immigrants who attended the centres with a symptom questionnaire followed by one-step IGRA (QuantiFERON-TB Gold In-Tube. Carnegie, Cellestis, Australia), a whole blood ELISA, containing ESAT-6 (early secretory antigenic target-6), CFP-10 (culture filtrate protein-10), and TB7 (Rv2654), which
was done in accordance with the manufacturer’s instructions. Results were positive, negative, or indeterminate, dependent on the manufacturer’s criteria. A meta-analysis of the effectiveness of the QuantiFERON-TB Gold In-Tube suggests that sensitivity is 84% and specificity is 99%. Immigrants who were symptomatic or who had a positive IGRA result were referred for chest radiography and further clinical assessment to discount active tuberculosis. Immigrants who were symptomatic or who had a positive IGRA result were referred for chest radiography and further clinical assessment to discount active tuberculosis.

We defined latent tuberculosis infection as immigrants with a positive IGRA and normal chest radiography in the absence of any clinical features that would suggest active disease. Immigrants who were diagnosed with latent infection were offered chemoprophylaxis with either 3 months of rifampicin and isoniazid, or 6 months of isoniazid, in accordance with UK guidelines, dependent on clinician and patient preference.

### Statistical analysis

We obtained data for demographics (age categorised as <16 years, 16–25 years, or 26–35 years, and sex), BCG vaccination status (ascertained through documentary evidence, reliable history of vaccination, or a characteristic scar), and country of origin. From reported country of origin, we further classified data into region of origin (Europe and the Americas, Middle East and north Africa, other Asia, Indian subcontinent, or sub-Saharan Africa) and we took tuberculosis incidence in the country (categorised as 0 cases per 100 000/year–50 cases per 100 000/year; 51/100 000–150/100 000; 151/100 000–250/100 000; 251/100 000–350/100 000, and ≥350/100 000) from WHO’s 2009 global report on tuberculosis.

### Table 1: Demographics and risk factors associated with IGRA positivity in immigrants

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Number in total cohort (n=1229)</th>
<th>Number of IGRA-positive individuals/total number tested (n=245)</th>
<th>Unadjusted OR (95% CI)</th>
<th>p value</th>
<th>Adjusted OR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;16*</td>
<td>36 (3%)</td>
<td>7/36 (19%)</td>
<td>1</td>
<td>0.005</td>
<td>1†</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>16–25</td>
<td>589 (48%)</td>
<td>86/589 (15%)</td>
<td>0.7 (0.3–1.7)</td>
<td>..</td>
<td>0.9 (0.4–2.1)</td>
<td>..</td>
</tr>
<tr>
<td>26–35</td>
<td>604 (49%)</td>
<td>152/604 (25%)</td>
<td>1.4 (0.6–3.2)</td>
<td>..</td>
<td>1.7 (0.7–4.1)</td>
<td>..</td>
</tr>
</tbody>
</table>

**Sex**

|            | Male 600 (49%)                  | 136/600 (23%)                                               | 1.4 (1.1–1.9)          | ..     | 1.3 (1.0–1.8)        | ..     | |

**Origin**

|            | Europe, Americas 50 (4%)        | 2/50 (4%)                                                  | 1                      | 0.0011 | ..                   | ..     | |
|            | Middle East, North Africa 26 (2%) | 1/26 (4%)                                                   | 1.0 (0.1–11.1)         | ..     | ..                   | ..     | |
|            | Other Asia 162 (13%)            | 29/162 (18%)                                               | 3.2 (1.2–8.8)          | ..     | ..                   | ..     | |
|            | Indian subcontinent 740 (60%)   | 144/740 (20%)                                              | 3.8 (1.4–9.4)          | ..     | ..                   | ..     | |
|            | Sub-Saharan Africa 251 (20%)    | 69/251 (28%)                                               | 9.1 (2.3–38.1)         | ..     | ..                   | ..     | |

**Incidence of tuberculosis in country of origin (cases per 100 000 population per year)**

|            | 0–50 32 (3%)                   | 1/32 (3%)                                                   | 1                      | <0.0001† | 1**                  | 0.006  | |
|            | 51–150 150 (12%)               | 19/150 (13%)                                               | 4.5 (0.6–34.9)         | ..     | 4.5 (0.6–35.3)       | ..     | |
|            | 151–250 835 (68%)              | 164/835 (20%)                                              | 7.6 (1.0–55.9)         | ..     | 7.9 (1.1–58.3)       | ..     | |
|            | 251–350 139 (11%)              | 41/139 (30%)                                               | 13.0 (1.7–98.2)        | ..     | 13.3 (1.8–101.5)     | ..     | |
|            | >350 73 (6%)                   | 20/73 (27%)                                                | 11.7 (1.5–91.5)        | ..     | 13.1 (1.7–102.7)     | ..     | |

**BCG vaccinated?**

|            | No 113 (17%)                   | 16/113 (14%)                                               | 1                      | 0.17    | ..                   | ..     | |
|            | Yes 544 (83%)                  | 107/544 (20%)                                              | 1.5 (0.8–2.6)          | ..     | ..                   | ..     | |

IGRA=interferon-γ release assay. OR=odds ratio. *Of the 36 individuals aged <16 years, one (2.8%) was aged ≤4 years, one (2.8%) was 5–9 years, and 34 (94.4%) were 10–15 years. †χ² p for trend. ‡Mutually adjusted for sex and incidence of tuberculosis in country of origin. §p value denotes overall effect of age in the model. ¶Mutually adjusted for age and tuberculosis incidence in country of origin. ||Region of origin and tuberculosis incidence in country of origin were strongly correlated; therefore, in the multivariate analysis, region of origin was left out. **Mutually adjusted for age and sex.
Continuous data were summarised with median and IQR, and were compared with the non-parametric Mann-Whitney U-test. Categorical responses were expressed as a simple descriptive percentage with 95% CIs, and comparisons were made with Pearson χ² or Fisher’s exact test as appropriate. We calculated yield of latent infection as the proportion of individuals who were IGRA positive; indeterminate results were included in the denominator when calculating IGRA-positivity. We assessed univariate associations of the presence of latent infection with age, sex, region of origin, tuberculosis incidence in country of origin, and BCG status using logistic regression, and reported as crude odds ratios (OR) and 95% CIs. We then calculated adjusted ORs by mutually adjusting in a multivariate logistic regression model (OR) and 95% CIs. We then calculated adjusted ORs by mutually adjusting in a multivariate logistic regression model. We considered screening using QuantiFERON-TB Gold In-Tube alone and varying the incidence threshold in the country of origin at which individuals became eligible for screening. At each threshold cutoff, we assessed the number of immigrants who would be eligible for screening. Because screening of children is a priority in tuberculosis control, and because the number of child immigrants younger than 16 years is small, we also considered screening all children irrespective of tuberculosis incidence in their country of origin.

Analyses used STATA version 9.2. All tests were two-tailed and p values less than 0·05 were regarded as significant.

Economic analysis
Economic analysis was done from a UK National Health Service perspective to consider two main questions related to use of a one-step IGRA strategy over 20 years. What are the costs of screening at different incidence thresholds? And is screening at specific thresholds cost effective and, if so, which threshold if any is the most cost effective? We developed a decision tree (webappendix pp 12–15) to simulate the clinical (number of cases of active tuberculosis), and economic outcomes of screening a hypothetical cohort of 10 000 new immigrants aged 35 years and younger for latent infection over a 20-year timeline.

We considered screening using QuantiFERON-TB Gold In-Tube alone and varying the incidence threshold in the country of origin at which individuals became eligible for screening. At each threshold cutoff, we assessed the number of immigrants who would be eligible for screening. Because screening of children is a priority in tuberculosis control, and because the number of child immigrants younger than 16 years is small, we also considered screening all children irrespective of tuberculosis incidence in their country of origin.

Role of the funding source
The funding sources played no part in the study design, data analysis, writing of the manuscript or decision to submit for publication. None of the investigators were paid to write this article by a pharmaceutical company or other agency. The corresponding author had full access to the data and had final responsibility for the decision to submit for publication.

Results
Recruitment into the study is outlined in figure 1. Table 1 shows the demographics of the screened population (n=1229). 1193 (97%) of screened immigrants were mostly young adults (aged 16–35 years) and attendees were less...
likely to be male than female (odds ratio [OR] 0·6, 95% CI 0·5–0·9). Data for previous BCG vaccination were available for only 657 participants, of whom about 80% had been vaccinated. Screened immigrants most commonly originated from the Indian subcontinent and sub-Saharan Africa; Pakistan and India were the most common countries of origin (32% and 26%, respectively). Overall, the screened immigrants were broadly representative of the foreign-born population in the UK; however, our study population contained slightly more immigrants from the Indian subcontinent, and slightly fewer from sub-Saharan Africa than the national average.31

IGRA results were available for all participants. Overall, 245 individuals tested positive (20%, 95% CI 18–22%), 982 were negative (80%, 77–82%), and two had indeterminate results (<1%, 0–1%). Participants attending the Westminster centre had a significantly lower proportion of IGRA-positive results than did those attending the Leeds and Blackburn centres (p=0·02). The proportions of positive immigrants aged less than 16 years, 16–25 years, and 26–35 years were 19%, 15%, and 25%, respectively. In multivariate analysis, male sex, increasing age, and tuberculosis incidence in country of origin were associated with positive IGRA (table 1, figure 2).

Table 2 outlines the outcomes of immigrant screening for latent infection stratified by age and incidence in the immigrants’ countries of origin. In all age groups, as the incidence threshold at which screening is instigated increases, fewer immigrants within the cohort are eligible to be screened and, consequently, the number of identified latent cases also decreases. Application of NICE guidance to our cohort would result in 271 individuals out of 1229 (22%) being eligible for screening, of whom 72 (27%) were IGRA positive, representing 29% of all cases of latent infection. Decreasing the screening threshold for adults to 150 cases per 100 000 (with the threshold for individuals aged <16 years unchanged) increases the number of immigrants who are eligible for screening to 1049 (85%) of 1229 (p<0·0001), with a similar proportionate yield of 226 out of 1049 (22%) and significantly more latent cases identified (92%, p<0·0001) than with NICE guidance.

Table 3 shows the results of the health-economic analysis, including the predicted number of tuberculosis cases and associated costs for each protocol in a cohort of 10 000 immigrants over 20 years. Although strategies that used screening with IGRA were more expensive than no screening, they also resulted in fewer cases of active tuberculosis in the 20-years. Costs increased as the threshold of incidence in country of origin at which immigrants were eligible to be screened fell (table 3). Screening of all immigrants aged 35 years and under...

### Table 3: Projected cases of active tuberculosis and associated costs with screening immigrants at different thresholds of tuberculosis incidence

<table>
<thead>
<tr>
<th>Screening Strategy</th>
<th>Cases of active tuberculosis over 20 years</th>
<th>Costs over 20 years (2010 £)</th>
<th>Incremental cases of active tuberculosis prevented over 20 years†</th>
<th>Incremental costs over 20 years‡ ($)</th>
<th>ICER (£ per tuberculosis case prevented)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No screening &lt;16 year olds</td>
<td>Screen 0 16–35 year olds</td>
<td>95 4</td>
<td>608 370·0</td>
<td>Baseline</td>
<td>Baseline</td>
</tr>
<tr>
<td>Screen &lt;16 year olds, 401</td>
<td>Screen 16–35 year olds, 500</td>
<td>91·9</td>
<td>678 586·5</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td></td>
<td>Screen 16–35 year olds, 400</td>
<td>91·8</td>
<td>681 710·0</td>
<td>Strict dominance</td>
<td>Strict dominance</td>
</tr>
<tr>
<td></td>
<td>Screen 16–35 year olds, 450</td>
<td>91·7</td>
<td>681 267·9</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td></td>
<td>Screen 16–35 year olds, 350</td>
<td>90·8</td>
<td>697 208·7</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td></td>
<td>Screen 16–35 year olds, 300</td>
<td>87·1</td>
<td>765 433·6</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td></td>
<td>Screen 16–35 year olds, 250</td>
<td>83·4</td>
<td>823 312·8</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td></td>
<td>Screen 16–35 year olds + sub-Saharan Africa, 500</td>
<td>82·2</td>
<td>850 103·1</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td></td>
<td>Screen 16–35 year olds, 200</td>
<td>71·1</td>
<td>1 121 093·2</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td></td>
<td>Screen 16–35 year olds, 150**</td>
<td>54·2</td>
<td>1 431 928·5</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td></td>
<td>Screen 16–35 year olds, 100</td>
<td>53·7</td>
<td>1 456 820·1</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td></td>
<td>Screen 16–35 year olds, 40</td>
<td>50·9</td>
<td>1 527 478·5</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td></td>
<td>Screen all &lt;16y</td>
<td>50·9</td>
<td>1 532 256·6</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td>Screen all 16–35 year olds</td>
<td>50·9</td>
<td>1 532 256·6</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
</tbody>
</table>

Arranged in order of increasing effectiveness—ie, fewer cases of active tuberculosis for a hypothetical cohort of 10 000 immigrants over 20 years. When different strategies are ranked from least effective to most effective (ie, number of cases of active tuberculosis that are predicted to occur), the incremental cost-effectiveness ratios (ICER) of most screening options, including present National Institute for Health and Clinical Excellence (NICE) guidance, are excluded through extended dominance. Incremental number of cases are calculated as the difference (ie, number of cases prevented) from the previous non-dominated option. Incremental costs are calculated as the difference (ie, extra £) from the previous non-dominated option. The situation occurring if screening included immigrants from the Indian subcontinent.

The situation occurring if screening was done by UK national (NICE) guidance. The numbers of cases are calculated as the difference (ie, number of cases prevented) from the previous non-dominated option. Incremental costs are calculated as the difference (ie, extra £) from the previous non-dominated option. The situation occurring if screening was done by UK national (NICE) guidance. The situation occurring if screening included immigrants from the Indian subcontinent.
from any countries irrespective of tuberculosis incidence would cost more than £1.5 million and prevent 44-5 cases of tuberculosis, whereas application of NICE guidance would cost about £850 000 and prevent 13-2 cases of active disease. Although no immigrant screening for latent tuberculosis infection was the least expensive option (£600 000), it resulted in the most cases of active tuberculosis.

After exclusion of dominated strategies (table 3), four cost-effective strategies remained. In decreasing order of cost-effectiveness, these strategies were (in addition to screening immigrants younger than 16 years from countries ≥40/100 000) to screen 16–35 year olds from any countries irrespective of tuberculosis incidence. The associated ICERs were £17 956·0, £20 818·8, £29 403·1, and £101 938·3, respectively, per active case averted. Therefore, for ICERs, the most cost-effective strategies would be to start screening at 40 cases per 100 000 for individuals aged less than 16 years, and 250 per 100 000 for 16–35 year olds. However, the ICER for the next most cost-effective strategy (screening individuals aged less than 16 years at 40 per 100 000 and 16–35-year-olds at 150 per 100 000) was only just under £3000 higher than the most cost-effective strategy. Strategies to further reduce the threshold to include screening all immigrants aged 35 years and younger from countries with incidences of 40 cases per 100 000 and higher, or indeed all immigrants, were both non-dominated options; however, the associated ICERs were very high.

Numbers needed to screen and numbers needed to treat (NNT) ranged from 165.5 to 231·9 and 42·0 to 42.7 respectively. Screening 16–35-year-olds at 250 per 100 000 had the lowest NNT (42.0), whereas screening at a threshold higher than this value generally resulted in a higher NNT.

Table 4 and webappendix (p 10–11) show results of the univariate sensitivity analysis. Changing several of the variables affected estimates for the ICERs of each of the strategies but did not significantly affect the rank order of the most cost-effective strategies. The most important variables were the rate at which new-entrants progress to active tuberculosis and the prevalence of latent tuberculosis in the screened cohort. Increased values for both variables increased cost-effectiveness (ie, lower ICERs). Cost-effectiveness was significantly more affected by diagnostic specificity than by sensitivity. Reductions in specificity increased ICER estimates (ie, reduced cost-effectiveness) because more false-positive, uninfected
individuals would be treated unnecessarily. Reductions in screening costs for latent infection, or assessment of those who screened positive, significantly reduced ICER values (ie, increased cost-effectiveness).

Discussion
Our assessment of the outcomes and cost-effectiveness of immigrant screening with IGRA at different incidence thresholds showed that new entrants to the UK have a high prevalence of latent infection, which varies by age, sex, and tuberculosis incidence in their country of origin (panel 2). UK national guidance for which groups to screen excludes most immigrants with latent infection, and our analysis suggests that policy could be modified in centres undertaking or considering the implementation of one-step IGRA testing to substantially reduce tuberculosis incidence while remaining cost effective.

In our cohort, the prevalence of latent infection was moderately high at 20%. Past studies from various settings, which used tuberculin skin test to diagnose latent infection recorded 34–55% of immigrants to be skin-test-positive. These high proportions are likely to show cross reactivity of past vaccination with BCG, resulting in many false-positive skin-test results. Therefore, the main implication of screening with the skin test is that an increased number of uninfected individuals will be unnecessarily treated with chemoprophylaxis. However IGRA, which have a high specificity in BCG-vaccinated patients, result in fewer false-positives than occur with tuberculin skin tests and, therefore, might provide a reduced, but accurate, estimated prevalence of latent infection in immigrants.

Data for the burden of latent infection diagnosed by IGRA in immigrants are scarce and relate generally to immigrant tuberculosis contacts or undocumented immigrants. These studies from various parts of Europe, including the UK, have suggested that 15–38% of new entrants have positive IGRA results.

Immigrants to the UK (other than from within the EU) arrive largely from countries with the highest burdens of tuberculosis. In our cohort, about 81% of all screened immigrants and just less than 87% of all cases of latent infection were from the Indian subcontinent and sub-Saharan Africa. However, by including several UK centres with different patterns of migration, we provide reliable estimates for the prevalence of latent infection in immigrants arriving from countries with a wide range of tuberculosis burden. Prevalence of latent infection was correlated independently with tuberculosis incidence in the immigrants’ country of origin. No immigrants from countries with incidences less than 50 cases per 100 000 had a positive IGRA; a finding that is consistent with small-scale European studies that used only a binary classification of incidence less than or greater than 50 cases per 100 000.

Increased age was also independently associated with an increased likelihood of a positive IGRA result. Although past work from both developed and developing countries has shown that IGRA positivity correlates with increasing age, with no prospective data, whether this correlation represents a truly higher prevalence of latent infection (due to more cumulative exposure in settings with high burdens of tuberculosis) or suboptimum IGRA-sensitivity in younger individuals is unclear.

Evidence has shown that many areas of the UK do not follow national guidelines for screening of latent infection and have set their own criteria for screening, and, indeed, our data suggest that NICE’s 2006 cutoff in 16–35-year-olds might be too high and restrictive. If we applied national guidance (which has been in place since 2006) in our cohort to those aged 35 years and younger, only 29% of latent infections would be identified, leaving nearly three-quarters (mostly those from the Indian subcontinent) undiagnosed and at risk of developing active disease and possibly infecting others. Indeed, these immigrants from the Indian subcontinent constitute the largest proportion of foreign-born patients with tuberculosis in the UK. If the threshold incidence in the country of origin for screening 16–35-year-olds were reduced to 150/100 000, 92% of those with latent infections would be identified, leaving only a small fraction undiagnosed and at risk of developing active disease.

Our health-economic analysis indicated that for one-step IGRA screening of 16–35-year-olds, four incidence thresholds were cost effective, and all were more cost effective than the threshold that is currently recommended by national guidance. The two most cost-effective strategies were to screen at 250/100 000 and higher (with an ICER of £7 956·0 per tuberculosis case averted) and to screen at 150/100 000, which would avert an additional
29.2 cases of active disease per 10000 immigrants (compared to screening at ≥250/100000) at a marginally increased ICER of £20818·8 per each additional case averted. This second strategy would encompass individuals from many Asian countries who are currently excluded, including those from the Indian subcontinent who form a large proportion of immigrants to the UK. Further reduction of the threshold to 40 cases per 100000 or even lower (ie, screening all immigrants) would prevent further cases of active infection; however, starting screening at these reduced thresholds would incur substantially increased total costs—therefore, resource availability and the funds that policy makers are willing to spend to control the incidence of active tuberculosis would need to be reconsidered.

Past health-economic analyses compared tuberculin skin-test with chest radiography for screening new-entrants from countries with high burdens of tuberculosis (especially for active tuberculosis).48,49 Although Schwartzman and colleagues48 reported that screening with chest radiographs was more cost effective than with skin tests, this conclusion might not be universally relevant because the investigators assumed that most unscreened immigrants developing active disease would need prolonged in-patient management. By contrast, Dasgupta and colleagues50 have compared several scenarios of immigrant screening, including chest radiography, tuberculin skin test, and IGRA, and shown that all techniques had a modest effect on tuberculosis notifications; chest radiography alone was the most cost-effective option. However, the model was based on putative scenarios rather than on actual data, and assumed a very low prevalence of latent infection in new immigrants (0·08–2·1%) and a low rate of reactivation. Our study advances the evidence base by using unique, accurate, and empirical IGRA screening data from various centres to objectively apply parameters to a decision model for assessing the key question of yields and cost-effectiveness of immigrant screening at different levels of incidence.

Although we chose a conservative progression rate from latent tuberculosis to active tuberculosis, of 5% over 20 years, this rate remains poorly understood. Marks and colleagues51 calculated a progression rate of 6·7% over 40 years in tuberculosis skin-test-positive (≥15 mm) refugees from southeast Asia.5 However, data from the UK,51 in a population similar to ours, suggest that over 10-years, about 13% of skin-test-positive, untreated immigrants (mostly from the Indian subcontinent) progress to active tuberculosis. These data mean that our results probably underestimate the true cost-effectiveness. Further work should ascertain whether the actual rates of disease progression in IGRA-positive immigrants after arrival and, specifically, whether this rate differs according to age and country of origin.

The success of screening will depend on implementation of robust systems, which will allow immigrants to be identified in a timely fashion; however, the overall effect of screening will be largely determined by patient and physician adherence both to having the diagnostic test, and to completing the chemoprophylactic drug regimen. A more specific blood test (ie, IGRA) might increase compliance in immigrants compared to two visits for skin tests, which are frequently false positive in this BCG-vaccinated population.52,54

Our work had several limitations. Routine surveillance data are likely to under report the prevalence of infection, whereas any selection bias in which immigrants attended for screening could increase the prevalence of latent infection in our study. Moreover, we did not have concurrent results for tuberculin skin test against IGRA because the participating centres do not routinely do skin tests in new-entrants. One of the most substantial obstacles with test performance is the scarcity of a gold-standard test for latent tuberculosis, which makes it difficult to calculate the sensitivity of diagnostic tests for this infection. We therefore used figures from the most up-to-date meta-analysis of IGRA performance in which culture-confirmed active tuberculosis was the surrogate reference standard.22 Because IGRA sensitivity is likely to be lower in patients with active tuberculosis than in healthy individuals undergoing screening for latent infection, this assumption might underestimate the sensitivity of the test and therefore the cost-effectiveness estimates. By contrast, if specificity estimates are based on preselected patients with a very low probability of tuberculosis, the test specificity might be overestimated. Increased estimates would give fewer false-positive results, thereby overestimating the cost-effectiveness of screening.

In our health-economic analysis we made some assumptions about the natural history of tuberculosis (eg, onward transmission to contacts and complete clearance of infection, with no risk of reinfection after chemoprophylaxis) because this was not a formal dynamic model that would allow us to capture the intrinsic transmission dynamics of tuberculosis. Although we included secondary cases of active and latent tuberculosis, incorporation of tertiary and quaternary cases would further increase cost-effectiveness. Moreover, we did not incorporate drug-resistant strains or HIV infection. Although data from our study parameterised the model, uncertainty surrounds several variables for which we made assumptions—eg, we assumed that there were no prevalent cases of active tuberculosis in the screened cohort, but, in reality, a small proportion of individuals proved to have active disease as a result of screening. By not incorporating these factors into the decision-analysis, our analysis could underestimate the cost-effectiveness of screening. By contrast, we assumed that all patients with
active disease would be diagnosed, accepted, and, complete, treatment, and this assumption could result in overestimation of cost-effectiveness.

Unlike NICE’s cost-utility analysis in which assessments of different strategies are made using cost per quality-adjusted life-year, like other investigators, we assessed effectiveness as cost per tuberculosis case prevented,9-11,14 because objective data on quality-adjusted life-years are still scarce for patients with active tuberculosis and for those receiving chemoprophylaxis.

As national guidelines are developed for screening of latent tuberculosis with new techniques (such as IGRA), they will need to quantitatively integrate the prevalence of latent infection in immigrant populations from different regions to formulate policy that cost-effectively improves tuberculosis control and prevention.13 Finally, although we assessed the cost-effectiveness of screening at different thresholds with one-step IGRA, further work should compare different screening protocols (such as skin test with IGRA vs skin-test alone vs IGRA alone) and different IGRA tests (QuantiFERON-TB Gold In-Tube vs T-SPOT.TB vs next-generation IGRA).14,59-60

Contributors
MP collected and analysed the immigrant screening data and wrote the first draft of the manuscript. JPW, LPO, OMK, and GW collected the immigrant screening data as part of routine service provision and were involved in revising the manuscript. IA and PJW were involved in drafting the manuscript and providing advice on statistical and health-economic analysis. AL conceived the idea to undertake the multicentre study and was involved in drafting and revising the manuscript and analysing the data.

Conflicts of interest
AL invents patents underpinning T-cell-based diagnosis. The IFN-gamma ESAT-6/CFP-10 ELISPOT was commercialised by an Oxford University spin-out company (T-SPOT.TB; Oxford Immunotec Ltd, Abingdon, UK) in which Oxford University and Professor Lalvani have minority shares of equity and royalty entitlements. MP, JPW, LPO, OMK, GW, IA, and PJW declare that they have no conflict of interest.

Acknowledgements
MP is funded by a Medical Research Council Capacity Building grant. AL is a Wellcome Senior Research Fellow in Clinical Science and NIHR Senior Investigator. We thank all staff who assisted in extracting data from the various databases.

References
37 Gibney KB, Mihrshahi S, Torresi J, Marshall C, Leder K, Biggs BA.
36 WHO. Global tuberculosis control: epidemiology, strategy,
35 Lalvani A, Pareek M. A 100 year update on diagnosis of tuberculosis
34 WHO. Tuberculosis: global surveillance, research, and response
33 Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison
32 Offi ce for National Statistics. Final mid-2009 population estimates:
31 Office for National Statistics. Country of birth by primary care
gov.uk/dissemination/ (accessed Nov 23, 2010).
30 WHO. Global tuberculosis control: epidemiology, strategy,
29 Bakir M, Dosanjh DP, Deeks JJ, et al. Use of T cell-based diagnosis
28 Mahomed H, Hawkridge T, Verver S, et al. The tuberculin skin test
prognostic value of IFN-γ release assay and tuberculin skin test in
22 WHO. Global tuberculosis control: epidemiology, strategy,